JPS62209091A - Antitumor active polysaccharide - Google Patents

Antitumor active polysaccharide

Info

Publication number
JPS62209091A
JPS62209091A JP61050993A JP5099386A JPS62209091A JP S62209091 A JPS62209091 A JP S62209091A JP 61050993 A JP61050993 A JP 61050993A JP 5099386 A JP5099386 A JP 5099386A JP S62209091 A JPS62209091 A JP S62209091A
Authority
JP
Japan
Prior art keywords
reaction
neutral
polysaccharide
color
sulfuric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61050993A
Other languages
Japanese (ja)
Other versions
JPH0372084B2 (en
Inventor
Shozo Oikawa
及川 昭蔵
Yoshiro Sato
吉朗 佐藤
Toshirou Yadomae
宿前 利郎
Naohito Ono
尚仁 大野
Masumi Osawa
大沢 真澄
Yoshiyuki Suzuki
良幸 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Beet Sugar Manufacturing Co Ltd
Original Assignee
Nippon Beet Sugar Manufacturing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Beet Sugar Manufacturing Co Ltd filed Critical Nippon Beet Sugar Manufacturing Co Ltd
Priority to JP61050993A priority Critical patent/JPS62209091A/en
Publication of JPS62209091A publication Critical patent/JPS62209091A/en
Publication of JPH0372084B2 publication Critical patent/JPH0372084B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

NEW MATERIAL:Antibiotic grifolan-N having the following physical and chemical properties. Elemental analysis (%): C 38.9-40.1, H 5.8-6.0, N <= determination limit. Molecular weight (gel filtration method): 1X10<5>-1X10<7> distribution. Melting point: 230 deg.C (decomposition). Specific rotatory power: [alpha]D=29.2+ or -0.5 (C=0.1, H2O). Solubility: readily soluble in water, alkali and dimethyl sulfoxide, insoluble in ethyl alcohol, ether, etc. Color reaction: positive in Molish reaction and negative in iodine reaction, etc. Appearance: white cotton state, etc. USE:An anti-cancer drug. PREPARATION:For example, a mycelium of Grifola frondosa var tokachiana (FERM P-4979) is subjected to contact reaction in a liquid medium containing one or more of low-molecular saccharide (e.g. glucose, etc.), high-molecular saccharide (e.g. starch, etc.), etc., at acidic pH at 20-30 deg.C for 2-8 days.

Description

【発明の詳細な説明】 (産業上の利用分野) この発明はマイタケを利用して得る抗腫瘍活性多糖に関
する。
DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) This invention relates to an anti-tumor active polysaccharide obtained using Maitake mushrooms.

(従来技術) 従来から、キノコに由来する抗腫瘍活性物質は数多く知
られ、マイタケについても多く、例えば特公昭52−4
4386号公報の天然又は合成の栄養液体培地にマイタ
ケを培養して得る培養済培地から制癌物質を抽出する方
法とか特開昭6Q−58925号公報のマイタケ子実体
から抽出する抗腫瘍活性物質等がある。
(Prior art) Many anti-tumor active substances derived from mushrooms have been known, including many for maitake, for example,
4386, a method for extracting anticancer substances from a cultured medium obtained by culturing maitake in a natural or synthetic nutrient liquid medium, and JP-A-6Q-58925, an antitumor active substance extracted from maitake fruiting bodies, etc. There is.

(発明が解決しようとする問題点) ・上記従来技術において例えば特公昭52−44386
号公報の方法にあっては、培養済培地を原料とすること
から、抽出物に混入する各種有機・無機成分の分離、精
製に複雑な多数の手間を要する不都合があり、特開昭6
0−5892号公報に示すものにあっては原料として子
実体を用いるため原料の十分なる確保において問題なし
としない不都合を有している。
(Problems to be solved by the invention) - In the above-mentioned prior art, for example, Japanese Patent Publication No. 52-44386
Since the method disclosed in the publication uses a cultured medium as a raw material, it has the disadvantage that it requires a lot of complicated time and effort to separate and purify various organic and inorganic components mixed in the extract.
The method disclosed in Japanese Patent Publication No. 0-5892 uses fruiting bodies as raw materials, and therefore has the disadvantage that there is no problem in securing sufficient raw materials.

(問題点を解決するための手段) 上記した如く、従来の技術にあっては、目的物の分離、
精製が複雑であるとか、原料供給において問題が残って
いるとかで尚改善の余地を残すものであった。
(Means for solving the problem) As mentioned above, in the conventional technology, separation of the target object,
There was still room for improvement due to the complexity of purification and problems remaining in the supply of raw materials.

上記に鑑み、この発明者らは鋭意研究した結果、この発
明者らの一部の者の発明になる特公昭59−18995
号公報に記載するマイタケ菌糸体を糖質溶液に接触させ
て得る多糖体について更に検討したところ意外にも抗腫
瘍活性のあることを見い出し、この知見に基づき上記で
得た多糖から中性成分を分画したところ、この両分に高
い抗j!l!瘍活性のあることを認め、理化学的分析の
結果、以下に詳記するように、β1→6分技を有するβ
1→3グルカンであることを認めこの発明を完成した。
In view of the above, as a result of intensive research, the inventors of the present invention published the patent publication No. 59-18995, which was invented by some of the inventors.
When we further investigated the polysaccharide obtained by contacting maitake mycelium with a carbohydrate solution, we unexpectedly found that it had antitumor activity, and based on this knowledge, we extracted neutral components from the polysaccharide obtained above. When fractionated, both fractions had high anti-J! l! It was confirmed that there was tumor activity, and as a result of physical and chemical analysis, as detailed below,
He recognized that it was a 1→3 glucan and completed this invention.

(イ)元素分析値 C38,9〜40.1%、H5,8
〜6.0%N定量限界以下 (+])分子量(ゲル濾過法)lxlO5〜lX107
に分布(ハ)融 点 230℃で分解 (ニ)比旋光度〔α3D +29.2±0.5(C=0
.1.1120)(ホ)赤外線吸収スペクトル(KBr
法)第1図のとおり (へ) 13C−NMRスペクトル(DMSO−d、中
) 第2図のとおり (ト)溶剤に対する溶解性 水、アルカリ、ジメチルスルフオキシド([)MSO)
に易溶、エチルアルコール、メチルアルコール、エーテ
ル、アセトン等の有機溶剤には不溶。
(a) Elemental analysis value C38.9-40.1%, H5.8
~6.0% N quantification limit (+) Molecular weight (gel filtration method) lxlO5 ~ lx107
Distributed to
.. 1.1120) (e) Infrared absorption spectrum (KBr
Method) As shown in Figure 1 (F) 13C-NMR spectrum (DMSO-d, middle) As shown in Figure 2 (G) Solubility in solvents Water, alkali, dimethyl sulfoxide ([) MSO)
Easily soluble in organic solvents such as ethyl alcohol, methyl alcohol, ether, and acetone.

(チ)呈色反応 モーリッシュ反応、アンスロン硫酸反応、フェノール硫
酸反応はいずれも陽性を呈し、ヨード反応、ニンヒドリ
ン反応、ビユレット反応はいずれも陰性を呈す。
(H) Color reactions The Molisch reaction, the Anthrone sulfuric acid reaction, and the phenol sulfuric acid reaction all give a positive result, and the iodine reaction, the ninhydrin reaction, and the Biillet reaction all give a negative result.

(す)塩基性、酸性、中性の別 水溶液は中性を示す (ス)物質の色、形状  白色、綿状 (作 用) この発明で用いるマイタケ菌糸はシロマイタケ、クロマ
イタケの一般に知られるマイタケを液体又は固体培養基
で培養して得るマイタケ菌糸体であり、これらマイタケ
は天然のマイタケから分離し純粋培養、継代培養によっ
て形質が保持されているもの、或は各種保存機関にある
菌株を同じようにしてその形質を保持させているものい
ずれも用いることができ、例えば保存菌株としてグリフ
ォラ フロンドッサ(Grifola frondos
a) IFO4911゜IFo 7040等、天然から
得られたものとして、グリフォラ フロンドッサ・パル
・トカチアーナ(Grifola frondosa 
var tokachiana)(微工研菌寄第497
9号)等を挙げることができ、中でもグリフォラ・フロ
ンドッサ・パル・トカチアーナの使用が好ましい。
(S) Basic, acidic, neutral Aqueous solution is neutral (S) Color and shape of substance White, flocculent (Action) Maitake mycelia used in this invention are commonly known as Shiromaitake and Kuromaitake. Maitake mycelium is obtained by culturing Maitake mushrooms in a liquid or solid culture medium, and these Maitake mushrooms are those that have been isolated from natural Maitake mushrooms and have retained their characteristics through pure culture or subculture, or strains that are stored in various preservation institutions. Any strain that maintains its characteristics in the same way can be used, for example, as a preserved strain, Grifola frondos
a) IFO4911゜IFo7040, etc., which are obtained from nature, such as Grifola frondosa pal Tocatiana (Grifola frondosa pal Tocatiana)
var tokachiana) (Fiber Engineering Laboratory No. 497
No. 9), among which Grifola frondosa pal Tocatiana is preferred.

いま、グリフォラ・フロンドッサ・パル・トカチアーナ
を用いてのこの発明の多糖について説明すると、この菌
株の継代培養物を予め液体或は固体培地により培養して
得た菌糸体を適当な手段により集菌し、必要に応じて水
洗を行った後、好ましくは無菌水に単一に分散懸濁させ
、これをアラビノース、キシロース、フラクトース、グ
ルコース、マンノース、ガラクトース、マルトース、シ
ュクロース、メリビオース、ラクトース、ラフィノース
、イノシトール、マニトール等の低分子糖類、デンプン
、デキストリン、アラビアゴムのような高分子糖類、グ
リコシド類或はこれらの加水分解物、又は精製糖蜜、製
糖工程中の精製粘液等の一種又は二種以上を含む糖質溶
液をクエン酸、乳酸のような有機酸によりpHを酸性域
としたものに添加し、攪拌を行いながら20〜30℃、
2〜8日間接触反応を行うと、菌糸体が酵素的に糖質に
作用して溶液中に多量の多糖を生成するに至る。
Now, to explain the polysaccharide of this invention using Grifola frondosa pal Tocatiana, the mycelium obtained by culturing a subculture of this strain in advance in a liquid or solid medium is collected by appropriate means. After rinsing with water if necessary, it is preferably dispersed and suspended in sterile water, and this is mixed with arabinose, xylose, fructose, glucose, mannose, galactose, maltose, sucrose, melibiose, lactose, raffinose, One or more of low molecular weight sugars such as inositol and mannitol, high molecular weight sugars such as starch, dextrin, and gum arabic, glycosides or their hydrolysates, refined molasses, and purified mucus during the sugar refining process. Add the carbohydrate solution containing the carbohydrate to a solution whose pH has been adjusted to an acidic range with an organic acid such as citric acid or lactic acid, and heat at 20 to 30°C while stirring.
When the contact reaction is carried out for 2 to 8 days, the mycelium acts enzymatically on the carbohydrates and produces a large amount of polysaccharides in the solution.

上記反応の終了後、菌糸体と上澄液とに分離し、分離し
た上澄液を濃縮するか或は濃縮することなしに糖不溶性
溶媒例えばメタノール、エタノール等のアルコール、ア
セトンを添加して沈でんを生成せしめる。このとき通常
はエチルアルコールを使用する。このような溶媒による
沈でん生成を必要に応じ複数回行った後、沈でん物を分
離、乾燥すると殆ど白色の綿状物を得る。
After the above reaction is completed, the mycelium and the supernatant are separated, and the separated supernatant is concentrated or precipitated by adding a sugar-insoluble solvent such as methanol, alcohol such as ethanol, or acetone without concentrating. is generated. At this time, ethyl alcohol is usually used. After forming a precipitate with such a solvent multiple times as necessary, the precipitate is separated and dried to obtain an almost white flocculent material.

、上記で得た白色の綿状物を尿素溶液又は水に溶解し、
HCO,−型に再生したDEAE−セファデックスA−
25を用いてクロマト分離し、中性画分を分取し。
, dissolve the white flocculent obtained above in urea solution or water,
DEAE regenerated into HCO,-type-Sephadex A-
25 to separate the neutral fraction.

これに前記と同様のアルコール等の溶媒を加えて沈でん
を生成せしめると白色綿状の本発明の多糖を得る。この
場合において、尿素溶液に溶解した場合には、溶解性が
よいが、中性画分から尿素を除去するために透析を必要
とする。−力水に溶解した場合には、中性画分の透析を
不要とする利点があるが尿素溶液に比べて若干溶解に時
間を要することになる。従って前記物質の溶解に尿素溶
液を用いるか水を用いるかは事情によって適宜選択。
A white cotton-like polysaccharide of the present invention is obtained by adding a solvent such as alcohol as described above to form a precipitate. In this case, when dissolved in a urea solution, the solubility is good, but dialysis is required to remove urea from the neutral fraction. - When dissolved in water, it has the advantage of not requiring dialysis of the neutral fraction, but it takes a little longer to dissolve than in a urea solution. Therefore, whether to use a urea solution or water to dissolve the substance should be selected depending on the circumstances.

すればよい。do it.

上記のようにこの発明の多糖は、マイタケ菌糸体を糖質
溶液に接触させて得る物質から、その中性画分を選択的
に取り出すだけで、従来のように前処理に複雑な多くの
精製を不要とし、中性画分の単離、精製に必要に応じて
透析を行う程度で十分に純粋な多糖を得ることができる
As mentioned above, the polysaccharide of this invention can be produced by simply selectively extracting the neutral fraction from the material obtained by contacting maitake mycelium with a carbohydrate solution. is not necessary, and a sufficiently pure polysaccharide can be obtained by performing dialysis as necessary for isolation and purification of the neutral fraction.

以上にて得た多糖は、以下に示す理化学的分析結果から
β(1→3)結合するグルコース残基3ケごとにβ(1
→6)結合するグルコース残基1ケの分枝を有するβ−
グルカンであることが知れ、この多糖をGrifola
n−Nと名づける。
The polysaccharide obtained above has β(1 → 3) bonded glucose residues for every 3 β(1 → 3) bonded glucose residues, according to the physical and chemical analysis results shown below.
→6) β- with one branched glucose residue attached
It is known that this polysaccharide is a glucan, and this polysaccharide is called Grifola.
Name it n-N.

このGrifolan−Nは後述の実施例で説明するよ
うに高い抗腫瘍活性を示す。
This Grifolan-N exhibits high antitumor activity as explained in the Examples below.

理化学的分析 (1)元素分析値等 C: 3g、9〜40.1%、H: 5.8〜6.0%
、N:定量限界以下、ハロゲン、硫黄は定量されない。
Physical and chemical analysis (1) Elemental analysis values, etc. C: 3g, 9-40.1%, H: 5.8-6.0%
, N: Below the quantification limit, halogen and sulfur are not quantified.

(2)分子量 0.2モルNaOH/8モル尿素平衡セファロースCL
−4B(ファーマシア・ジャパン)カラムによるゲル濾
過クロマトグラフィーにより分子量の分布範囲がlXl
0’ 〜lX10’t’ある。
(2) Molecular weight 0.2 mol NaOH/8 mol urea equilibrium Sepharose CL
-4B (Pharmacia Japan) column gel filtration chromatography revealed a molecular weight distribution range of 1X1
0' to lX10't'.

(3)融点 約230℃で熱分解する。(3) Melting point It decomposes thermally at about 230°C.

(4)比旋光度 20℃における水中濃度0.1g/100mQの[α]
(4) [α] at a concentration of 0.1 g/100 mQ in water at a specific optical rotation of 20°C
.

が29.2±0.5を示す。shows 29.2±0.5.

(5)溶解性 水、アルカリ、ジメチルスルフオキシド(DMSO)に
易溶、エチルアルコール、メチルアルコール、エーテル
、アセトン等の有機溶媒には不溶である。
(5) Solubility: Easily soluble in water, alkali, and dimethyl sulfoxide (DMSO), but insoluble in organic solvents such as ethyl alcohol, methyl alcohol, ether, and acetone.

(6)水溶液の塩基性、酸性、中性の別1%水溶液は中
性域(pH6,3〜6.5)を示す。
(6) Basic, acidic, and neutral aqueous solutions A 1% aqueous solution exhibits a neutral range (pH 6.3 to 6.5).

(7)構成糖の種類 三弗化酢酸(CF、C00H)による加水分解物を水素
化ホウ素ナトリウム(Na[304)に還元し、これの
アルジトールアセテート誘導体をガスクロマトグラフィ
ー分析した結果、グルコースのみを明確に検出し、フコ
ース、キシロース、マンノース、ガラクトース等の他の
糖は検出しない。
(7) Types of constituent sugars Hydrolyzate with trifluoroacetic acid (CF, C00H) was reduced to sodium borohydride (Na[304), and the alditol acetate derivative thereof was analyzed by gas chromatography. As a result, only glucose was found. is clearly detected, and other sugars such as fucose, xylose, mannose, and galactose are not detected.

(8)構成糖の結合様式 箱守法によるメチル化分析の結果は、2,3,4゜6−
チトラメチルー〇−0−グリシドール: 2,4.6−
トリメチルー〇−D−グリシドール:2,4−ジメチル
−〇−D−グリシドールが1.0:1.7:1.0の比
で3.4.6−トリメチルー〇−D−グリシドール、2
,6−シメチルー〇−〇−グリシドールが痕跡であるこ
とから、1→3結合D−グルコース残基3個ごとに1→
6結合D−グルコースの分枝を有するグルカンを繰り返
し単位とすることが知られる。
(8) Binding mode of constituent sugars The results of methylation analysis using the Hakomori method are 2, 3, 4°6-
Chitramethyl-0-glycidol: 2,4.6-
Trimethyl-〇-D-glycidol: 2,4-dimethyl-〇-D-glycidol in a ratio of 1.0:1.7:1.0, 3.4.6-trimethyl-〇-D-glycidol, 2
,6-dimethyl-〇-〇-glycidol is a trace, so for every three 1→3 bonded D-glucose residues, 1→
It is known that glucan having 6-linked D-glucose branches is used as a repeating unit.

(9)スミス分解生成物 完全スミス分解により、生成物としてグルコースとグリ
セリンを検出し、緩和スミス分解物の透析外液からグリ
セリンをそして内液の加水分解液からグルコースのみを
検出したことから、1→3結合とC−6に分枝を有する
構造のグルカンであることが知れる。
(9) Smith Decomposition Products Glucose and glycerin were detected as products by complete Smith decomposition, and glycerin was detected from the external dialysis fluid of the relaxed Smith decomposition product, and only glucose was detected from the hydrolysis fluid of the internal fluid.1 → It is known that it is a glucan with a structure having 3 bonds and a branch at C-6.

(10)赤外線吸収スペクトル JASCOIRA−1型分先々度計を用いKBr法で測
定した結果は第1図のとおりで、波数894cm−1に
βグリコシド結合配向に特徴的な吸収(P)を認めるこ
とから、β−グリコシド結合構造であることが認められ
る。
(10) Infrared absorption spectrum The results measured by the KBr method using a JASCOIRA-1 type point-to-point meter are shown in Figure 1, and an absorption (P) characteristic of β-glycosidic bond orientation is observed at a wave number of 894 cm-1. From this, it is recognized that it is a β-glycoside bond structure.

(11)”C−NMRスペクトル 重ジメチルスルフオキシド(DMSO−d、 )に溶解
し、JEOL−FX200スペクトルメーターにより6
0℃で測した結果は第2図のとおりで、δ値67ppm
域のβ(l→6)結合に含まれるC−6の炭素の帰属を
含むシグナルS工と、δ値8Sppm域のβ(l→3)
結合に含まれるC−3の炭素に帰属するシグナルS2と
、δ値1103pp域のβ−結合のC−1の炭素に帰属
するシグナルが特徴的に認められ、更にシグナルS2が
3つのピークを示すことから、β(1→3)結合が3個
あり、β(1→6)が1個あるβ−グルカン構造が知ら
れる。
(11)” C-NMR spectrum dissolved in deuterated dimethyl sulfoxide (DMSO-d, ) and measured by JEOL-FX200 spectrometer.
The results measured at 0°C are shown in Figure 2, with a δ value of 67 ppm.
Signal S engineering including the assignment of C-6 carbon included in the β (l → 6) bond in the region and β (l → 3) in the δ value 8 Sppm region
A signal S2 attributed to the C-3 carbon included in the bond and a signal attributed to the C-1 carbon of the β-bond in the δ value range of 1103 pp are characteristically recognized, and furthermore, the signal S2 shows three peaks. Therefore, a β-glucan structure is known that has three β(1→3) bonds and one β(1→6) bond.

(12)呈色反応 モーリッシュ反応、アンスロン硫酸反応、フェノール硫
酸反応はいずれも陽性を呈し、ヨード反応は陰性でα(
1→4)結合グルカンの存在を示さず、ニンヒドリン反
応、ビューレット反応が共に陰性であることから蛋白質
、ペプチドの存在を示さない。
(12) The color reactions Morish reaction, Anthrone sulfuric acid reaction, and phenol sulfuric acid reaction all showed positive results, and the iodine reaction showed negative α(
1→4) It does not show the presence of bound glucan, and the ninhydrin reaction and Biuret reaction are both negative, so it does not show the presence of protein or peptide.

以上述べたようにこの発明の抗腫瘍活性多糖Grifo
lan−Nは高い抗腫瘍活性を示すことから、薬用とし
て有用で、腹腔内投与、腫瘍的投与、静脈内投与として
利用できるほか、経口投与としての利用も期待しうるも
のであり、各種形の制がん剤用途を有するものである。
As mentioned above, the antitumor active polysaccharide Grifo of the present invention
Since lan-N exhibits high antitumor activity, it is useful medicinally and can be used for intraperitoneal administration, tumor administration, intravenous administration, and can also be used for oral administration, and is available in various forms. It has anticancer drug uses.

以下実施例によってより具体的に説明する。This will be explained in more detail below with reference to Examples.

(実施例) 実施例1 予め継代培養しているグリフォラ フロンドッサ パル
 トカチアーナ(Grifola frondosa 
varTokachiana) (微工研菌寄第497
9号)を含む培地面から、5m+sX5mmの切片を2
片取り出し、これをマルトエキス4%、おがくずエキス
5%、麩エキス5%、寒天25%、pi s、sのオー
トクレーブ処理済の斜面に接種して25℃、3週間培養
して一次種菌とする。上記−次種菌から5mmX5mm
の切片を3片取り出し、これをせ蔗糖′Wi2%(糖量
として)。
(Example) Example 1 Pre-subcultured Grifola frondosa pal Tocatiana
varTokachiana)
Cut 2 sections of 5 m + s x 5 mm from the medium surface containing No. 9).
Take a piece and inoculate it onto an autoclaved slope of 4% malt extract, 5% sawdust extract, 5% wheat extract, 25% agar, pis, s, and culture at 25°C for 3 weeks to use as a primary inoculum. . 5mm x 5mm from the above - next inoculum
Take out 3 sections and mix them with 2% sucrose (as sugar content).

ポリペプトン0.4%を含み10%乳酸でPH5,5に
調整したオートクレーブ処理培地50鵬Qに接種して2
5℃で3日間静置培養して二次種菌とする。この二次種
菌の5rtrQ宛をプルコース2%、甘蔗糖蜜2%(糖
量として)、ポリペプトン0.6%、大豆油3滴を含み
、10%乳酸でpH4,5に調整したオートクレーブ処
理済培地100tR宛を分注した500社容量坂ロフラ
スコの2本に夫々接種し、25℃、2週間で振盪培養し
てこれを三次種菌とする。上記で得た種菌の全量をグル
コース2%、せ蔗糖′f12%(11i量として)、ポ
リペプトン0.6%、大豆油0.1%を含み、10%乳
酸でpH4,5に調整したオートクレーブ処理済培地6
Qを収容する1O12容量ジャーファーメンタ−に投入
し、通気量0.5VVM、温度25℃、攪拌数25Or
、P、Imで6日間培養した。
Inoculated into 50 Peng Q autoclaved medium containing 0.4% polypeptone and adjusted to pH 5.5 with 10% lactic acid.
A secondary inoculum is obtained by statically culturing at 5°C for 3 days. This secondary inoculum to 5rtrQ was added to an autoclaved medium containing 2% pullose, 2% cane molasses (as sugar content), 0.6% polypeptone, 3 drops of soybean oil, and adjusted to pH 4.5 with 10% lactic acid. The mixture was inoculated into two 500-capacity Sakaro flasks each containing 100 tR, and cultured with shaking at 25°C for 2 weeks to use as a tertiary inoculum. The total amount of the inoculum obtained above was autoclaved containing 2% glucose, 12% sucrose (as 11i amount), 0.6% polypeptone, and 0.1% soybean oil, and adjusted to pH 4.5 with 10% lactic acid. Completed medium 6
Pour Q into a 1012 capacity jar fermenter, aeration rate 0.5VVM, temperature 25℃, stirring number 25Or.
, P, and Im for 6 days.

上記ジャーファーメンタ−培養で得た内容物を遠心分離
(30QOr、p、m、 5分)して集菌し、水洗−遠
心分離を2回行った後、これによって得た菌糸体の全量
をグルコース5%、クエン1o、s%、pH4,0の糖
質液6Qを収容するlOQ容量ジャーファーメンタ−に
投入し、通気量0.5VVM、 28℃、攪拌数25O
r、p、mで2日間反応させた後内容物を遠心分離して
菌糸体と上澄液に分離し、上澄液にエタノール濃度40
容量%となるようにエタノールを加えて沈でん物を生成
せしめ、遠心分離後凍結乾燥して。
The contents obtained in the jar fermentor culture described above were centrifuged (30 QOr, p, m, 5 minutes) to collect bacteria, and after washing with water and centrifuging twice, the total amount of mycelia obtained was collected. A 10Q capacity jar fermenter containing 6Q of carbohydrate solution with 5% glucose, 10, s% citric acid, and pH 4.0 was charged into a jar fermenter with aeration rate of 0.5 VVM, 28°C, and stirring number 250.
After reacting for 2 days at R, P, and M, the contents were centrifuged to separate the mycelia and supernatant, and the supernatant was diluted with ethanol at a concentration of 40
Ethanol was added to make a precipitate by volume%, and the precipitate was centrifuged and freeze-dried.

乾燥物6.5gを得た。上記遠心分離によって残留した
反応済の菌糸体により、上記と同じ糖質を用いて第2回
の反応を行い同様に乾燥物5.8gを得た。
6.5 g of dry matter was obtained. Using the reacted mycelium remaining after the centrifugation, a second reaction was carried out using the same carbohydrate as above to obtain 5.8 g of a dried product in the same manner.

更に第2回の反応で残留した反応済の菌糸体により上記
と同じ糖質を用いて第3回の反応を行い(但し反応日数
を3日とした)同様に乾燥物5.0gを得た。
Furthermore, a third reaction was carried out using the same carbohydrates as above using the reacted mycelium remaining in the second reaction (however, the number of days for the reaction was set to 3 days), and 5.0 g of dried product was obtained in the same manner. .

上記第1回〜第3回で得た乾燥物をよく混合し。Thoroughly mix the dried products obtained in the first to third steps above.

これの1gを8モル尿素水溶液におよそ2 mg/mQ
で溶解し、これをHCO3″″型に再生したDEAE−
セルファデックスA−25200mRを充填するカラム
を用いて中性画分(尿素溶液溶出素通り区分)を分取し
、セルロースチューブ(白井松器械/製)で72時間透
析し、内液に1.5倍量のエタノールを加えて沈でんを
生成せしめ、これを凍結乾燥して白色の綿状もしくは微
細繊維様の本発明の抗腫瘍活性多糖Grifolan−
N O,6gを得た。このものは前記した理化学的性質
を示した。
Add 1 g of this to an 8 molar urea aqueous solution at approximately 2 mg/mQ.
DEAE-
A neutral fraction (passing through the urea solution eluate) was collected using a column packed with Cellphadex A-25200mR, dialyzed for 72 hours with a cellulose tube (manufactured by Shiraimatsu Kikai), and the internal solution was 1.5 times amount of ethanol is added to form a precipitate, which is lyophilized to form a white flocculent or fine fiber-like antitumor active polysaccharide Grifolan-
Obtained 6 g of NO. This product showed the above-mentioned physical and chemical properties.

実施例2 実施例1で得たGrifolan−Nの抗腫瘍活性(其
の1)IRC−系6週令のマウス(雄、体重27〜30
g) 10匹を1群としてサルコーマ180腫瘍細胞5
X10’ケをそけい部皮下に接種し、これを零日とし、
前記Grifolan−Nを生理食塩水に試験量宛溶解
した試験液を1.3,5.7及び9日目の5回にわたり
、各種経路で投与し、腫瘍細胞の接種後35日目に解体
し、IIIR瘍増殖の抑止率と完全退縮の程度を調査し
たところ、第1表のとおりでGrifolar+−Hの
腫瘍増殖の抑制作用の高いことを認めた。
Example 2 Antitumor activity of Grifolan-N obtained in Example 1 (Part 1) IRC-strain 6-week-old mice (male, weight 27-30
g) Sarcoma 180 tumor cells 5 in groups of 10 animals
X10' was inoculated subcutaneously in the groin area, and this was designated as day 0.
A test solution prepared by dissolving the aforementioned Grifolan-N in physiological saline in a test amount was administered via various routes five times on days 1.3, 5.7, and 9, and disassembled on the 35th day after inoculation of tumor cells. When the inhibition rate and degree of complete regression of IIIR tumor growth were investigated, as shown in Table 1, Grifolar+-H was found to have a high tumor growth inhibitory effect.

1)  *  P<0.05.   本I  P(0,
01,重水*  p<o、oot実施例3 実施例1で得たGrifolan−Nの抗腫瘍活性(其
の実施例2の要領に準じ、投与口を変えた場合の抑止率
を調査した。 IRC−系6週令のマウス(雄、体重2
7〜30g)を使用し、10匹を1群としてサルコーマ
180腫瘍細胞5X10’ケをそけい部皮下に接種し、
これを零日とする。生理食塩水に溶解したGrifol
an−Nの試験量を前記零日の前及び後の所定の日に夫
々腹腔内に投与し、零日の翌日から起算して35日目に
マウスを解体して腫瘍の状況を調査した。その結果は第
2表に示すとおりで腫瘍接種口以前の投与の場合にも高
い抑止効果を認めた。
1) *P<0.05. Book IP (0,
01, heavy water * p<o, oot Example 3 Antitumor activity of Grifolin-N obtained in Example 1 (according to the procedure of Example 2, the inhibition rate was investigated when the administration port was changed. IRC - strain 6 week old mice (male, weight 2
7 to 30 g), 5 x 10' Sarcoma 180 tumor cells were inoculated subcutaneously in the groin area in groups of 10 animals,
Let this be day zero. Grifol dissolved in saline
A test amount of an-N was intraperitoneally administered on predetermined days before and after day zero, and on the 35th day counting from the day after day zero, the mice were dissected and the state of the tumor was investigated. The results are shown in Table 2, and a high suppressive effect was observed even when administered before the tumor inoculation site.

このような前投与による抑止効果は、従来知られるマイ
タケ子実体から得た多糖物質(特開昭60−58925
号公報)と比べてGrifolan−Nに特徴的なもの
である。この前投与による効果のよって来る理由は未解
明であり、今後の研究に待たれるところである。
Such a deterrent effect due to pre-administration is due to the conventionally known polysaccharide substance obtained from the fruiting body of Maitake mushroom (Japanese Patent Application Laid-Open No. 60-58925
This is characteristic of Grifolan-N compared to the previous publication. The reason for this effect of pre-administration is unknown and awaits future research.

第2表 投 与 量 投与スケジュール    腫瘍重量(g)
   抑止率μg/回×回    (日)      
 平均±SD    (%)100X5   −9.−
7.−5.−3.−1   0.67±1.62   
86.2100X5    ÷1. +3. +5. 
+7. +11  1.13±3.57   76.7
100x5    +11.+13.+15.+17.
+19  0.73+1.29   84.9対照  
+1.43.45.+7.+9  4.84±3.78
  −(効 果) この発明によるときは、多糖の分画、精製がきわめて簡
単で、得られた多糖の抗腫瘍活性が高いものであるから
、腫瘍抑制剤としての利用価値がきわめて高いものであ
り、かつ安価に址産を可能とする。
Table 2 Dosage Dosage schedule Tumor weight (g)
Deterrence rate μg/times x times (day)
Average ± SD (%) 100X5 -9. −
7. -5. -3. -1 0.67±1.62
86.2100X5 ÷1. +3. +5.
+7. +11 1.13±3.57 76.7
100x5 +11. +13. +15. +17.
+19 0.73+1.29 84.9 control
+1.43.45. +7. +9 4.84±3.78
- (Effect) According to the present invention, fractionation and purification of the polysaccharide are extremely easy, and the obtained polysaccharide has high antitumor activity, so it has extremely high utility value as a tumor suppressor. , and allows for cheap leftover production.

【図面の簡単な説明】[Brief explanation of drawings]

第1図はこの発明のGrifolan−Nの赤外線吸収
スペクトル。 第2図はこの発明のGrifolan−Nの13C−N
MRスペクトルを示す。
FIG. 1 shows the infrared absorption spectrum of Grifolan-N of the present invention. Figure 2 shows 13C-N of Grifolan-N of this invention.
An MR spectrum is shown.

Claims (1)

【特許請求の範囲】 下記の理化学的性質を有する抗腫瘍活性多糖Grifo
lan−N。 (イ)元素分析値 C38.9〜40.1%、H5.8
〜6.0%N定量限界以下 (ロ)分子量 ゲル濾過法により1×10^5〜1×1
0^7に分布 (ハ)融点 230℃で熱分解 (ニ)比旋光度〔α〕_D 29.2±0.5(C=0
.1、H_2O) (ホ)赤外線吸収スペクトル(KBr法) 第1図に示
すとおり (ヘ)^1^3C−NMRスペクトル(DMSO−d_
6中) 第2図に示すとおり (ト)溶剤に対する溶解性 水、アルカリ、ジメチルスルフオキシドに易溶、エチル
アルコール、メチルアルコール、エーテル、アセトン等
の有機溶剤に不溶 (チ)呈色反応 モーリッシュ反応、アンスロン硫酸反応、フェノール硫
酸反応はいずれも陽性を呈し、ヨード反応、ニンヒドリ
ン反応、ビュレット反応はいずれも陰性を呈す。 (リ)塩基性、酸性、中性の別 水溶液は中性を示す (ヌ)物質の色、形状 白色 綿状
[Claims] Antitumor active polysaccharide Grifo having the following physicochemical properties
lan-N. (a) Elemental analysis value C38.9-40.1%, H5.8
~6.0% N quantification limit (b) Molecular weight: 1 x 10^5 - 1 x 1 by gel filtration method
Distribution at 0^7 (c) Melting point Thermal decomposition at 230℃ (d) Specific optical rotation [α]_D 29.2±0.5 (C=0
.. 1, H_2O) (e) Infrared absorption spectrum (KBr method) As shown in Figure 1 (f) ^1^3C-NMR spectrum (DMSO-d_
6) As shown in Figure 2, (g) Solubility in solvents, Easily soluble in water, alkali, dimethyl sulfoxide, Insoluble in organic solvents such as ethyl alcohol, methyl alcohol, ether, acetone, etc. (H) Color reaction mode. The Lisch reaction, Anthrone sulfuric acid reaction, and phenol sulfuric acid reaction all show positive results, and the iodine reaction, ninhydrin reaction, and Buret reaction all show negative results. (i) Basic, acidic, neutral Aqueous solution is neutral (n) Color and shape of substance White, flocculent
JP61050993A 1986-03-08 1986-03-08 Antitumor active polysaccharide Granted JPS62209091A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61050993A JPS62209091A (en) 1986-03-08 1986-03-08 Antitumor active polysaccharide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61050993A JPS62209091A (en) 1986-03-08 1986-03-08 Antitumor active polysaccharide

Publications (2)

Publication Number Publication Date
JPS62209091A true JPS62209091A (en) 1987-09-14
JPH0372084B2 JPH0372084B2 (en) 1991-11-15

Family

ID=12874311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61050993A Granted JPS62209091A (en) 1986-03-08 1986-03-08 Antitumor active polysaccharide

Country Status (1)

Country Link
JP (1) JPS62209091A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06312938A (en) * 1993-04-30 1994-11-08 Yukiguni Maitake:Kk Production of substance having promoting effect for hair tonicity
JPH06312934A (en) * 1993-04-30 1994-11-08 Yukiguni Maitake:Kk Production of substance having immunosuppressive effect
JPH08119874A (en) * 1994-10-24 1996-05-14 Takumi Sogabe Production of suppressor of aids virus and cancer cell
EP0893449A4 (en) * 1996-03-08 1999-04-07 Yukiguni Maitake Co Ltd Antitumor substance extracted from Grifola frondosa
US6616928B1 (en) 1998-10-20 2003-09-09 Yukiguni Maitake Co., Ltd. Active oxygen scavenger and cancer chemopreventer from Grifola
CN103819573A (en) * 2014-03-07 2014-05-28 北京联合大学 Ultrasonic wave assistant-catalyzed synthesis of grifolan sulphate
CN104277129A (en) * 2013-07-01 2015-01-14 周伯扬 Method for extracting grifola frondosa polysaccharides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5918995A (en) * 1982-07-23 1984-01-31 セイコーエプソン株式会社 Driving system for matrix display panel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5918995A (en) * 1982-07-23 1984-01-31 セイコーエプソン株式会社 Driving system for matrix display panel

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06312938A (en) * 1993-04-30 1994-11-08 Yukiguni Maitake:Kk Production of substance having promoting effect for hair tonicity
JPH06312934A (en) * 1993-04-30 1994-11-08 Yukiguni Maitake:Kk Production of substance having immunosuppressive effect
JPH08119874A (en) * 1994-10-24 1996-05-14 Takumi Sogabe Production of suppressor of aids virus and cancer cell
EP0893449A4 (en) * 1996-03-08 1999-04-07 Yukiguni Maitake Co Ltd Antitumor substance extracted from Grifola frondosa
US6616928B1 (en) 1998-10-20 2003-09-09 Yukiguni Maitake Co., Ltd. Active oxygen scavenger and cancer chemopreventer from Grifola
CN104277129A (en) * 2013-07-01 2015-01-14 周伯扬 Method for extracting grifola frondosa polysaccharides
CN103819573A (en) * 2014-03-07 2014-05-28 北京联合大学 Ultrasonic wave assistant-catalyzed synthesis of grifolan sulphate

Also Published As

Publication number Publication date
JPH0372084B2 (en) 1991-11-15

Similar Documents

Publication Publication Date Title
Misaki et al. Structural and immunochemical studies on D-arabino-D-mannans and D-mannans of Mycobacterium tuberculosis and other Mycobacterium species
US4357323A (en) Polysaccharide RBS substance and antitumor agent containing same
SU562202A3 (en) The method of obtaining derivatives of amino sugars
JPH08259602A (en) Novel polysaccharide substance
Montgomery et al. Isolation of 6-[α-D-glucopyranosyl]-D-glucose (isomaltose) from enzymic hydrolyzates of starch2
HU188599B (en) Process for preparing physiologically active substance designated as ch-1
Bell et al. 397. The structure of a cell-wall polysaccharide of Baker's yeast
JPS62209091A (en) Antitumor active polysaccharide
JPH0412960B2 (en)
Zähringer et al. Structure of a new 6-deoxy-α-d-talan from Burkholderia (Pseudomonas) plantarii strain DSM 6535, which is different from the O-chain of the lipopolysaccharide
US4614733A (en) Polysaccharides pharmaceutical compositions and the use thereof
US4398023A (en) β-1,3-Glucanpolyol, process for preparation thereof, and utilization thereof
CN100510094C (en) Production method of konjak mannose using cellulase
Manzoni et al. Production and purification of an extracellularly produced K4 polysaccharide from Escherichia coli
Bailey Transglucosidase activity of rumen strains of Streptococcus bovis: structure of the dextran produced from sucrose
KR19990081593A (en) Novel immunopotentiating polysaccharides and preparation method thereof
JPS60255733A (en) Beta-d-glucan
Kogan et al. Glucomannan from Candida utilis: structural investigation
Dixon et al. The specific substance from Pneumococcus type 34. The configuration of the glycosidic linkages
JP3061363B2 (en) Galactosulfate oligosaccharide, method for producing the same and use thereof
KR102007421B1 (en) Composition for anti-influenza virus comprising as active ingredient polysaccharide derived from Lactobacillus plantarum and method for producing the polysaccharide
WO1990001060A1 (en) Low molecular weight xylanase glycoprotein
JPH04288093A (en) Novel steviol glucoside and production thereof
WO1993012243A1 (en) A new fungal glukan and its preparation
JPS6359679B2 (en)